BioCentury
ARTICLE | Tools & Techniques

BioMarin's brainy buy

BioMarin finally buys Zacharon to target brain-specific lysosomal diseases

January 28, 2013 8:00 AM UTC

The winding down of a 2011 development deal between Zacharon Inc. and Pfizer Inc. gave erstwhile suitor BioMarin Pharmaceutical Inc. a new opening to buy the company.

The acquisition is also the latest in a string of endeavors by enzyme replacement therapy companies looking to crack the blood-brain barrier...